Cannon C. IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin mono- therapy on cardiovascular outcomes after acute coronary syndromes. Presented at: Annual Scien- tific Sessions of the American Heart Association, Chicago, IL, November 17, 2014....
编译自:IM Proved Reduction of Outcomes: Vytorin Efficacy International Trial.ACC. Nov 18, 2014
Clinical implications of the IMPROVE- IT trial in the light of current and future lipid-lowering treatment options. Expert Opin Pharmacother 2015 Nov 11. [Epub ahead of print] PMID: 26559810Serban MC, Banach M, Mikhailidis DP. Clinical implications of the IMPROVE-IT trial in the light of ...
Conclusions: Only one-third of current ACS patients would have qualified for the IMPROVE-IT trial. Compared to the trial population, they were older, sicker, and received less optimal secondary prevention therapies. Thus, it is unclear if the benefit seen with simvastatin/ezetimibe use in the tr...
In terms of safety, that is what I am most impressed with. This was a longer-term trial for ezetimibe than we have had before. And that makes a big difference, particularly when you’re pushing to lower values. In terms...
IMPROVE — IT ( IMProved R eduction of Outcomes : V ytori n E f f ica cy International Trial 『 进一步降低终点事 件 :葆至能疗效 国际试验] ) 是一项在 急性冠脉综合征的高危患者中确认葆 ( 依折麦布+辛伐他汀 ) 与辛伐他汀单药相 比的临床获 和安全性的国际多中心、双盲、随机对照临床试验...
The IMPROVE-IT trial was funded by Merck Sharp and Dohme. Cannon disclosed grants for clinical research from: Accumetrics.; AstraZeneca Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; CSL Behring; Essentialis; GlaxoSmithKline; Merck & Co; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceuticals North...
The IMPROVE-IT trial showed that the cholesterol-lowering drug ezetimibe, when added to simvastatin, provides greater improvement in cardiovascular outcomes among patients with diabetes vs those without diabetes in a population with acute coronary syndrome. Additionally, the rate of new-onset diabetes wa...
IMPROVE-IT IMProvedReductionofOutcomes:VytorinEfficacyInternationalTrial 进一步降低终点事件：葆至能疗效国际试验 一项多中心、双盲、随机研究，比较依折麦布/辛伐他汀与辛伐他汀单药治疗在患有ACS的高危患者中的临床获益和安全性 IMPROVE-IT研究背景 •LDL-C升高是冠心病的风险因素1•使用他汀类药物降低LDL-C可以...